» Articles » PMID: 35246933

Occult Hepatitis B Virus Infection in Hepatitis C Virus Negative Chronic Liver Diseases

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2022 Mar 5
PMID 35246933
Authors
Affiliations
Soon will be listed here.
Abstract

Data concerning the prevalence of hepatitis B virus (HBV) occult infection (OBI) varies greatly in the different studies according to the sensitivity and specificity of the diagnostic approaches and the HBV prevalence in the different populations examined. The clinical implications of OBI are still debated. While the impact of OBI in HBV transmission as well as in HBV reactivation under immunosuppression are well established, the role of OBI in liver disease and hepatocellular carcinoma (HCC) development are still not definitively elucidated. It has been hypothesized that OBI might contribute to worsening the liver disease course when other causes of liver damage co-exist. Furthermore, much evidence suggests a role of OBI in the hepato-carcinogenesis processes through both indirect and direct oncogenic mechanisms that might favour HCC development. Data on the OBI clinical implications mainly come from studies performed in patients with hepatitis C virus (HCV) infection. However, HCV prevalence has dramatically fallen in the past years also because of the advent of specific and highly effective direct acting antivirals, with a consequent abrupt change of the worldwide scenario of chronic liver disease. Information about OBI prevalence and possible clinical impact in non-HCV-related liver disease are fragmentary, and the objective of this review is to critically summarize the available data in this field.

Citing Articles

Occult Hepatitis B Virus Infection: An Update.

Saitta C, Pollicino T, Raimondo G Viruses. 2022; 14(7).

PMID: 35891484 PMC: 9318873. DOI: 10.3390/v14071504.


Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases.

Franze M, Pollicino T, Raimondo G, Squadrito G Liver Int. 2022; 42(5):963-972.

PMID: 35246933 PMC: 9310828. DOI: 10.1111/liv.15233.

References
1.
Raffetti E, Fattovich G, Donato F . Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016; 36(9):1239-51. DOI: 10.1111/liv.13142. View

2.
Caviglia G, Abate M, Tandoi F, Ciancio A, Amoroso A, Salizzoni M . Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. J Hepatol. 2018; 69(2):301-307. DOI: 10.1016/j.jhep.2018.03.021. View

3.
Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C . Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver Int. 2014; 34(6):e144-50. DOI: 10.1111/liv.12482. View

4.
Villa E, Grottola A, Buttafoco P, Trande P, Merighi A, Fratti N . Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci. 1995; 40(1):8-13. DOI: 10.1007/BF02063934. View

5.
Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View